A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma
- PMID: 12543806
A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma
Abstract
Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the ErbB receptor ligand family, exists in distinct molecular forms with disparate biological activities. Previous studies have shown that the HB-EGF precursor, proHB-EGF, localizes to the cytoplasm of transitional cells of the human bladder urothelium and that the soluble form of the growth factor is an autocrine urothelial cell mitogen. In this study, we identify a potential role for proHB-EGF in transitional cell carcinoma (TCC) of the bladder. In an analysis of 33 TCC specimens and 8 normal controls, proHB-EGF, identified using an antibody directed against the cytoplasmic tail domain, localized to cell nuclei in a manner that correlated positively with tumor stage and grade (P < 0.001). The ability of proHB-EGF to localize to the nucleus was independently confirmed in a TCC cell line (TCCSUP), in which approximately 40% of transfected proHB-EGF was found to reside in the nuclear compartment. In Kaplan-Meier survival analysis, TCC patients with >20% proHB-EGF-positive cell nuclei demonstrated markedly reduced survival compared with patients with <20% proHB-EGF-positive nuclei (P < 0.005, log-rank test). In multivariate analysis, nuclear localization of proHB-EGF of >20% was an independent prognostic indicator of disease-specific mortality. This is the first report in any cell type that HB-EGF is capable of translocating to the cell nucleus. In addition, our findings suggest that nuclear proHB-EGF may play a role in disease progression in bladder cancer and possibly other cancers.
Similar articles
-
Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.Cancer. 2007 May 15;109(10):2016-24. doi: 10.1002/cncr.22627. Cancer. 2007. PMID: 17394193
-
Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.Urol Oncol. 2004 Mar-Apr;22(2):93-101. doi: 10.1016/j.urolonc.2004.01.001. Urol Oncol. 2004. PMID: 15082004
-
Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma.Cancer Res. 1990 Apr 15;50(8):2530-7. Cancer Res. 1990. PMID: 1690599
-
Heparin-binding EGF-like growth factor: a juxtacrine growth factor.Cytokine Growth Factor Rev. 2000 Dec;11(4):335-44. doi: 10.1016/s1359-6101(00)00013-7. Cytokine Growth Factor Rev. 2000. PMID: 10959080 Review.
-
Dual intracellular signaling by proteolytic cleavage of membrane-anchored heparin-binding EGF-like growth factor.Cytokine Growth Factor Rev. 2004 Feb;15(1):13-9. doi: 10.1016/j.cytogfr.2003.10.002. Cytokine Growth Factor Rev. 2004. PMID: 14746810 Review.
Cited by
-
Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.Cell Death Dis. 2014 Feb 6;5(2):e1046. doi: 10.1038/cddis.2014.10. Cell Death Dis. 2014. PMID: 24503538 Free PMC article.
-
The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence.J Urol. 2015 Jan;193(1):19-29. doi: 10.1016/j.juro.2014.07.121. Epub 2014 Aug 23. J Urol. 2015. PMID: 25158272 Free PMC article. Review.
-
Membrane-bound trafficking regulates nuclear transport of integral epidermal growth factor receptor (EGFR) and ErbB-2.J Biol Chem. 2012 May 11;287(20):16869-79. doi: 10.1074/jbc.M111.314799. Epub 2012 Mar 28. J Biol Chem. 2012. PMID: 22451678 Free PMC article.
-
Epidermal growth factor cytoplasmic domain affects ErbB protein degradation by the lysosomal and ubiquitin-proteasome pathway in human cancer cells.Neoplasia. 2012 May;14(5):396-409. doi: 10.1596/neo.111514. Neoplasia. 2012. PMID: 22745586 Free PMC article.
-
Omeprazole and PGC-formulated heparin binding epidermal growth factor normalizes fasting blood glucose and suppresses insulitis in multiple low dose streptozotocin diabetes model.Pharm Res. 2013 Nov;30(11):2843-54. doi: 10.1007/s11095-013-1112-6. Epub 2013 Jun 21. Pharm Res. 2013. PMID: 23793991 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous